Boston Scientific (BSX) Price Target Raised to $121

by MarketNewsData

Strong product momentum and upbeat analyst revisions are keeping Boston Scientific on bullish radar ahead of its Q2 print.

  • Analyst Action: Raymond James’ Jayson Bedford maintains a Strong Buy rating and raises the price target to $121, implying a +16.6% upside.

  • Earnings Preview:

    • EPS Estimate: $0.72

    • Revenue Estimate: $4.89B

    • Both reflect ~18% year-over-year growth.

  • Analyst Sentiment:

    • While the exact ABR of 1.13 isn’t confirmed, consensus reflects a Strong Buy bias from Wall Street.

More Live News